Estonian company developing innovative genetics tests for cancer risk assessment, based on polygenic risk score technology is looking for distributors in various healthcare markets.

The Estonian health-tech company’s mission is to achieve better health and longer life for people empowering individuals, medical professionals, and public healthcare in using genetics for personal and public health activities. The company is ISO13485 certified health-tech company and a registered healthcare service provider (laboratory services; medical genetics, oncology) in Estonia. Their team consists of highly educated doctors, bioinformaticians, geneticists. The CEO of the company is an oncologist, who has more than 25 years of experience as a clinician, researcher, leader, and healthcare manager. For the first years, they have worked on the development of the products according to all applicable regulatory requirements and for the last year the company has been focused on implementation and building distribution networks in Europe. They have partners in UK, Latvia, Lithuania, Spain, Portugal, Greece, Switzerland. The tests are implemented via healthcare providers and medical device distributors. In Estonia, the company has around 12 000 patients, who have started cancer precision prevention. The company has brought four innovative CE-marked genetic tests relying on polygenic risk scores (in vitro medical devices, 98/79/EC) into clinical use. The tests assess individual genetic risk of developing cancer and give exact clinical recommendation when and how often to undergo clinical analysis depending on the personal risk level. Individual risks of cancer differ considerably between people because of genetic predispositions meaning that some individuals are at greatly increased risk compared to others. Therefore, cancer prevention should be made more precise to account for differences in individual risk. Preventive genetic testing is suitable for all adults! Products: CE-marked IVD level polygenic risk score tests for: • breast cancer; • prostate cancer; • colorectal cancer; • skin melanoma. The company is developing new PRS tests for other common diseases as well. The test results provide answers to the following questions: • What is my genetic risk level of specific cancer? • At what age should I start with specific clinical analysis and how often? • Should I take additional measures to prevent cancer? • What can I do to reduce my risk of developing the cancer? • What changes and symptoms do I need to look out for regarding specific cancer? They offer their products in discrete components that provide an opportunity to individualize the offering to customer needs. PRS tests can be performed with: • DNA data genotyping arranged by the company or distributor’s partner lab • DNA upload from third-party services (biobank data, 23andMe, MyHeritage, DNA-ancestry, Dante Labs, etc.) Also, the company has developed a platform to healthcare providers, distributors, and patients to manage the orders and test results. They have an end-to-end pipeline for implementing the tests in different settings: medical device distributors and healthcare service providers. The company wants to expand in Scandinavia and Central Europe countries and is looking to build long-term relationships with medical device distributors in various healthcare markets.